Eli Lilly and CompanyLLYNYSE
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 9.70% |
| Q3 2025 | 3.88% |
| Q2 2025 | 22.04% |
| Q1 2025 | -9.56% |
| Q4 2024 | 10.55% |
| Q3 2024 | 0.84% |
| Q2 2024 | 7.47% |
| Q1 2024 | -1.56% |
| Q4 2023 | 6.38% |
| Q3 2023 | 2.23% |
| Q2 2023 | 18.71% |
| Q1 2023 | -0.54% |
| Q4 2022 | 10.70% |
| Q3 2022 | 1.18% |
| Q2 2022 | 10.67% |
| Q1 2022 | -17.83% |
| Q4 2021 | 14.90% |
| Q3 2021 | 3.04% |
| Q2 2021 | -1.02% |
| Q1 2021 | -9.03% |
| Q4 2020 | 25.43% |
| Q3 2020 | 5.41% |
| Q2 2020 | -0.14% |
| Q1 2020 | -11.97% |
| Q4 2019 | 14.52% |
| Q3 2019 | -1.52% |
| Q2 2019 | 13.95% |
| Q1 2019 | -15.36% |
| Q4 2018 | 13.50% |
| Q3 2018 | 0.78% |
| Q2 2018 | 14.76% |
| Q1 2018 | -24.82% |
| Q4 2017 | 9.94% |
| Q3 2017 | 5.34% |
| Q2 2017 | 1.10% |
| Q1 2017 | -13.26% |
| Q4 2016 | 17.32% |
| Q3 2016 | -7.45% |
| Q2 2016 | 9.41% |
| Q1 2016 | -15.45% |